An evidence-based review of neuronal cholesterol role in dementia and statins as a pharmacotherapy in reducing risk of dementia

References

• Dementia [Internet]. [ cited 2020 Oct 13]. Available from: https://www.who.int/news-room/fact-sheets/detail/dementia
   Google Scholar
• What Is Dementia? Symptoms, Types, and Diagnosis [Internet]. National institute on aging. [cited 2020 Oct 13]. Available from: http://www.nia.nih.gov/health/what-dementia-symptoms-types-and-diagnosis
   Google Scholar
• What is Alzheimer’s? [Internet]. Alzheimer’s Disease and Dementia. [cited 2020 Oct 13]. Available from: https://alz.org/alzheimers-dementia/what-is-alzheimers
   Google Scholar
• Dubois MF, Hébert R. The incidence of vascular dementia in Canada: a comparison with Europe and East Asia. Neuroepidemiology. 2001;20(3):179–187.
   PubMed Web of Science ®Google Scholar
• Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic diseases in the elderly research group. Neurology. 2000;54(11 Suppl 5):S4–9.
   PubMed Web of Science ®Google Scholar
• Hajjar I, Schumpert J, Hirth V, et al. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol Biol Sci Med Sci. 2002;57(7):M414–418.
   PubMed Web of Science ®Google Scholar
• Jick H, Gl Z, Ss J, et al. Statins and the risk of dementia. Lancet. 2000;356(9242): 1627–1631.
   PubMed Web of Science ®Google Scholar
• Newman AB, Fitzpatrick AL, Lopez O, et al. Dementia and Alzheimer’s disease incidence in relationship to cardiovascular disease in the cardiovascular health study cohort. J Am Geriatr Soc. 2005;53(7):1101–1107.
   PubMed Web of Science ®Google Scholar
• Miida T, Takahashi A, Tanabe N, et al. Can statin therapy really reduce the risk of Alzheimer’s disease and slow its progression? Curr Opin Lipidol. 2005;16(6):619–623.
   PubMed Web of Science ®Google Scholar
• Loera-Valencia R, Goikolea J, Parrado-Fernandez C, et al. Alterations in cholesterol metabolism as a risk factor for developing Alzheimer’s disease: potential novel targets for treatment. J Steroid Biochem Mol Biol. 2019;190:104–114.
   PubMed Web of Science ®Google Scholar
• Blennow K, de Leon MJ, Zetterberg H. Alzheimer’s disease. Lancet. 2006;368(9533):387–403.
   PubMed Web of Science ®Google Scholar
• Wang H, Kulas JA, Wang C, et al. Regulation of beta-amyloid production in neurons by astrocyte-derived cholesterol. Proc Natl Acad Sci USA. 2021;118(33): e2102191118.
   PubMed Web of Science ®Google Scholar
• Tanzi RE, Bertram L. Twenty years of the Alzheimer’s disease amyloid hypothesis: a genetic perspective. Cell. 2005;120(4):545–555.
   PubMed Web of Science ®Google Scholar
• Isik AT. Late-onset Alzheimer’s disease in older people. Clin Interv Aging. 2010;5:307–311.
   PubMed Web of Science ®Google Scholar
• Profenno LA, Porsteinsson AP, Faraone SV. Meta-analysis of Alzheimer’s disease risk with obesity, diabetes, and related disorders. Biol Psychiatry. 2010;67(6):505–512.
   PubMed Web of Science ®Google Scholar
• Prince MJ. Vascular risk factors and atherosclerosis as risk factors for cognitive decline and dementia. J Psychosom Res. 1995;39(5):525–530.
   PubMed Web of Science ®Google Scholar
• Anstey KJ, Lipnicki DM, Low LF. Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. Am J Geriatr Psychiatry. 2008;16(5):343–354.
   PubMed Web of Science ®Google Scholar
• Reitz C, Tang MX, Manly J, et al. Plasma lipid levels in the elderly are not associated with the risk of mild cognitive impairment. Dement Geriatr Cogn Disord. 2008;25(3):232–237.
   PubMed Web of Science ®Google Scholar
• Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol. 2005;4(8):487–499.
   PubMed Web of Science ®Google Scholar
• Duron E, Hanon O. Vascular risk factors, cognitive decline, and dementia. Vasc Health Risk Manag. 2008;4(2):363–381.
   PubMedGoogle Scholar
• Blom K, Emmelot-Vonk MH, Koek HL. The influence of vascular risk factors on cognitive decline in patients with dementia: a systematic review. Maturitas. 2013;76(2):113–117.
   PubMed Web of Science ®Google Scholar
• Lambert JC, Heath S, Even G, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat Genet. 2009;41(10):1094–1099.
   PubMed Web of Science ®Google Scholar
• Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat Genet. 2009;41(2009):1088–1093.
   PubMed Web of Science ®Google Scholar
• Sparks DL, Hunsaker JC 3rd, Sw S, et al. Cortical senile plaques in coronary artery disease, aging, and Alzheimer’s disease. Neurobiol Aging. 1990;11(6):601–607.
   PubMed Web of Science ®Google Scholar
• Sparks DL, Scheff SW, Hunsaker JC 3rd, et al. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol. 1994;126(1):88–94.
   PubMed Web of Science ®Google Scholar
• Wood WG, Li L, Müller WE, et al. Cholesterol as a causative factor in Alzheimer’s disease: a debatable hypothesis. J Neurochem. 2014;129(4):559–572.
   PubMed Web of Science ®Google Scholar
• Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232(4746):34–47.
   PubMed Web of Science ®Google Scholar
• Pappolla MA, Bryant-Thomas TK, Herbert D, et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer’s amyloid pathology. Neurology. 2003;61(2):199–205.
   PubMed Web of Science ®Google Scholar
• Solomon A, Kivipelto M, Wolozin B, et al. Midlife serum cholesterol and increased risk of Alzheimer’s and vascular dementia three decades later. Dement Geriatr Cogn Disord. 2009;28(1):75–80.
   PubMed Web of Science ®Google Scholar
• Martín MG, Pfrieger F, Dotti CG. Cholesterol in brain disease: sometimes determinant and frequently implicated. EMBO Rep. 2014;15(10):1036–1052.
   PubMed Web of Science ®Google Scholar
• Zarrouk A, Vejux A, Mackrill J, et al. Involvement of oxysterols in age-related diseases and aging processes. Aging Res Rev. 2014;18:148–162.
   PubMed Web of Science ®Google Scholar
• Gamba P, Testa G, Gargiulo S, et al. Oxidized cholesterol as the driving force behind the development of Alzheimer’s disease. Front Aging Neurosci. 2015;7:119.
   PubMed Web of Science ®Google Scholar
• Testa G, Rosin D, Pole G, et al. Implication of oxysterols in chronic inflammatory human diseases. Biochim. 2018;153:220–231.
   PubMed Web of Science ®Google Scholar
• McGuinness B, O’Hare J, Craig D, et al. Cochrane review on ‘Statins for the treatment of dementia.’ Int J Geriatr Psychiatry. 2013;28(2):119–126.
   PubMed Web of Science ®Google Scholar
• Ledesma MD, Dotti CG, McIlhinney J. The conflicting role of brain cholesterol in Alzheimer’s disease: lessons from the brain plasminogen system. Biochem Soc Symp. 2005;72:129–138.
   Google Scholar
• Kim SW, Kang HJ, Jhon M, et al. Statins, and Inflammation: new therapeutic opportunities in psychiatry. Front Psychiatry. 2019;10:103.
   PubMed Web of Science ®Google Scholar
• Björkhem I, Meaney S. Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol. 2004;24(5):806–815.
   PubMed Web of Science ®Google Scholar
• Varma VR, Büşra Lüleci H, Oommen AM, et al. Abnormal brain cholesterol homeostasis in Alzheimer’s disease-a targeted metabolomic and transcriptomic study. NPJ Aging Mech Dis. 2021;7(1):11.
   PubMed Web of Science ®Google Scholar
• Dietschy JM, Turley SD. Thematic review series: brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res. 2004;45(8):1375–1397.
   PubMed Web of Science ®Google Scholar
• Reitz C, Frisardi V, Imbimbo B. Dyslipidemia and dementia: current epidemiology, genetic evidence, and mechanisms behind the associations. J Alzheimers Dis. 2012;30(Suppl 2):S127–145.
   PubMed Web of Science ®Google Scholar
• Fünfschilling U, Saher G, Xiao L, et al. Survival of adult neurons lacking cholesterol synthesis in vivo. BMC Neurosci. 2007 2;8:1.
   PubMed Web of Science ®Google Scholar
• Shobab LA, Hsiung G-YR, Feldman HH. Rediscovery of cerebrosterol. Lancet Neurol. 2005;4(12):841–852.
   PubMed Web of Science ®Google Scholar
• Meaney S, Lütjohann D, Diczfalusy U, et al. Formation of oxysterols from different pools of cholesterol as studied by stable isotope technique: cerebral origin of most circulating 24S-hydroxycholesterol in rats, but not in mice. Biochim Biophys Acta. 2000;1486(2–3):293–298.
   PubMed Web of Science ®Google Scholar
• Kuller LH. Statins and dementia. Curr Atheroscler Rep. 2007;9(2):154–161.
   PubMedGoogle Scholar
• Björkhem I, Lütjohann D, Breuer O, et al. Importance of a novel oxidative mechanism for elimination of brain cholesterol. Turnover of cholesterol and 24(S)-hydroxycholesterol in rat brain as measured with 18O2 techniques in vivo and in vitro. J Biol Chem. 1997;272(48):30178–30184.
   PubMed Web of Science ®Google Scholar
• Jin U, Park SJ, Park SM. Cholesterol metabolism in the brain and its association with parkinson’s disease. Exp Neurobiol. 2019;28(5):554–567.
   PubMed Web of Science ®Google Scholar
• Zhang J, Liu Q. Cholesterol metabolism and homeostasis in the brain. Protein Cell. 2015;6(4):254–264.
   PubMed Web of Science ®Google Scholar
• Dai L, Zou L, Meng L, et al. Cholesterol metabolism in neurodegenerative diseases: molecular mechanisms and therapeutic targets. Mol Neurobiol. 2021;58(5):2183–2201.
   PubMed Web of Science ®Google Scholar
• Allinquant B, Clamagirand C, Potier M-C. Role of cholesterol metabolism in the pathogenesis of Alzheimer’s disease. Curr Opin Clin Nutr Metab Care. 2014;17(4):319–323.
   PubMed Web of Science ®Google Scholar
• Mazein A, Watterson S, Hsieh W-Y, et al. A comprehensive machine-readable view of the mammalian cholesterol biosynthesis pathway. Biochem Pharmacol. 2013;86(1):56–66.
   PubMed Web of Science ®Google Scholar
• Sun J-H, Yu J-T TL, Tan L. The role of cholesterol metabolism in Alzheimer’s disease. Mol Neurobiol. 2015;51(3):947–965.
   PubMed Web of Science ®Google Scholar
• Arnaud C, Mach F. Pleiotropic effects of statins in atherosclerosis: role on endothelial function, inflammation, and immunomodulation. Arch Mal Coeur Vaiss. 2005 Jun;98(6):661–666.
   PubMedGoogle Scholar
• Jurevics H, Morell P. Cholesterol for synthesis of myelin is made locally, not imported into brain. J Neurochem. 1995;64(2):895–901.
   PubMed Web of Science ®Google Scholar
• Yu J-T, Tan L, Hardy J. Apolipoprotein E in Alzheimer’s disease: an update. Annu Rev Neurosci. 2014;37:79–100.
   PubMed Web of Science ®Google Scholar
• Poirier J. Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer’s disease. Trends Mol Med. 2003;9(3):94–101.
   PubMed Web of Science ®Google Scholar
• Vance JE, Hayashi H, Karten B. Cholesterol homeostasis in neurons and glial cells. Semin Cell Dev Biol. 2005;16(2):193–212.
   PubMed Web of Science ®Google Scholar
• Brown AJ, Jessup W. Oxysterols: sources, cellular storage and metabolism, and new insights into their roles in cholesterol homeostasis. Mol Aspects Med. 2009;30(3):111–122.
   PubMed Web of Science ®Google Scholar
• Pfrieger FW. Cholesterol homeostasis and function in neurons of the central nervous system. Cell Mol Life Sci. 2003;60(6):1158–1171.
   PubMed Web of Science ®Google Scholar
• Pitas RE, Boyles JK, Lee SH, et al. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim Biophys Acta. 1987;917(1):148–161.
   PubMed Web of Science ®Google Scholar
• Björkhem I. Rediscovery of cerebrosterol. Lipids. 2007;42(1):5–14.
   PubMed Web of Science ®Google Scholar
• Bogdanovic N, Bretillon L, Lund EG, et al. On the turnover of brain cholesterol in patients with Alzheimer’s disease. Abnormal induction of the cholesterol-catabolic enzyme CYP46 in glial cells. Neurosci Lett. 2001;314(1–2):45–48.
   PubMed Web of Science ®Google Scholar
• Papassotiropoulos A, Lütjohann D, Bagli M, et al. Plasma 24S-hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer’s disease. Neuroreport. 2000;11(9):1959–1962.
   PubMed Web of Science ®Google Scholar
• Lund EG, Guileyardo JM, Russell DW. cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc Natl Acad Sci USA. 1999;96(13):7238–7243.
   PubMed Web of Science ®Google Scholar
• Heverin M, Bogdanovic N, Lütjohann D, et al. Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer’s disease. J Lipid Res. 2004;45(1):186–193.
   PubMed Web of Science ®Google Scholar
• Saucier SE, Kandutsch AA, Clark DS, et al. Hepatic uptake and metabolism of ingested 24-hydroxycholesterol and 24(S),25-epoxycholesterol. Biochim Biophys Acta. 1993;1166(1):115–123.
   PubMed Web of Science ®Google Scholar
• Lund EG, Xie C, Kotti T, et al. Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. J Biol Chem. 2003;278(25):22980–22988.
   PubMed Web of Science ®Google Scholar
• Martin M, Dotti CG, Ledesma MD. Brain cholesterol in normal and pathological aging. Biochim Biophys Acta. 2010;1801(8):934–944.
   PubMed Web of Science ®Google Scholar
• Koldamova RP, Lefterov IM, Ikonomovic MD, et al. 22R-hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid-beta secretion. J Biol Chem. 2003;278(15):13244–13256.
   PubMed Web of Science ®Google Scholar
• Panzenboeck U, Balazs Z, Sovic A, et al. cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis at an in vitro blood-brain barrier constituted of porcine brain capillary endothelial cells. J Biol Chem. 2002;277(45):42781–42789.
   PubMed Web of Science ®Google Scholar
• Heverin M, Meaney S, Lütjohann D, et al. Crossing the barrier: net flux of 27-hydroxycholesterol into the human brain. J Lipid Res. 2005;46(5):1047–1052.
   PubMed Web of Science ®Google Scholar
• Laffitte BA, Repa JJ, Joseph SB, et al. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc Natl Acad Sci USA. 2001;98(2):507–512.
   PubMed Web of Science ®Google Scholar
• Callaghan MF, Freund P, Draganski B, et al. Widespread age-related differences in the human brain microstructure revealed by quantitative magnetic resonance imaging. Neurobiol Aging. 2014;35(8):1862–1872.
   PubMed Web of Science ®Google Scholar
• Cantuti-Castelvetri L, Fitzner D, Bosch-Queralt M, et al. Defective cholesterol clearance limits remyelination in the aged central nervous system. Science. 2018;359(6376):684–688.
   PubMed Web of Science ®Google Scholar
• Montagne A, Barnes SR, Sweeney MD, et al. Blood-brain barrier breakdown in the aging human hippocampus. Neuron. 2015;85(2):296–302.
   PubMed Web of Science ®Google Scholar
• Segarra M, Aburto MR, Acker-Palmer A. Blood-brain barrier dynamics to maintain brain homeostasis. Trends Neurosci. 2021;44(5):393–405.
   PubMed Web of Science ®Google Scholar
• Saeed AA, Genové G, Li T, et al. Effects of a disrupted blood-brain barrier on cholesterol homeostasis in the brain. J Biol Chem. 2014;289(34):23712–23722.
   PubMed Web of Science ®Google Scholar
• Zheng H, Koo EH. Biology and pathophysiology of the amyloid precursor protein. Mol Neurodegener. 2011;6(1):27.
   PubMed Web of Science ®Google Scholar
• Xiong H, Callaghan D, Jones A, et al. Cholesterol retention in Alzheimer’s brain is responsible for high beta- and gamma-secretase activities and Abeta production. Neurobiol Dis. 2008;29(3):422–437.
   PubMed Web of Science ®Google Scholar
• Marquer C, Laine J, Dauphinot L, et al. Increasing membrane cholesterol of neurons in culture recapitulates Alzheimer’s disease early phenotypes. Mol Neurodegener. 2014;9:60.
   PubMed Web of Science ®Google Scholar
• Refolo LM, Pappolla MA, LaFrancois J, et al. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer’s disease. Neurobiol Dis. 2001;8(5):890–899.
   PubMed Web of Science ®Google Scholar
• Refolo LM, Malester B, LaFrancois J, et al. Hypercholesterolemia accelerates the Alzheimer’s amyloid pathology in a transgenic mouse model. Neurobiol Dis. 2000;7(4):321–331.
   PubMed Web of Science ®Google Scholar
• Simons M, Keller P, De Strooper B, et al. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A. 1998;95(11):6460–6464.
   PubMed Web of Science ®Google Scholar
• Kojro E, Gimpl G, Lammich S, et al. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc Natl Acad Sci USA. 2001;98(10):5815–5820.
   PubMed Web of Science ®Google Scholar
• Schneider A, Schulz-Schaeffer W, Hartmann T, et al. Cholesterol depletion reduces aggregation of amyloid-beta peptide in hippocampal neurons. Neurobiol Dis. 2006;23(3):573–577.
   PubMed Web of Science ®Google Scholar
• Grimm MO, Grimm HS, Tomic I, et al. Independent inhibition of Alzheimer disease beta- and gamma-secretase cleavage by lowered cholesterol levels. J Biol Chem. 2008;283(17):11302–11311.
   PubMed Web of Science ®Google Scholar
• Hicks DA, Nalivaeva NN, Turner AJ. Lipid rafts and Alzheimer’s disease: protein-lipid interactions and perturbation of signaling. Front Physiol. 2012;3:189.
   PubMed Web of Science ®Google Scholar
• Wahrle S, Das P, Nyborg AC, et al. Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol Dis. 2002;9(1):11–23.
   PubMed Web of Science ®Google Scholar
• Cordy JM, Hussain I, Dingwall C, et al. Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Proc Natl Acad Sci USA. 2003;100(20):11735–11740.
   PubMed Web of Science ®Google Scholar
• Ehehalt R, Keller P, Haass C, et al. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol. 2003;160(1):113–123.
   PubMed Web of Science ®Google Scholar
• Osenkowski P, Ye W, Wang R, et al. Direct and potent regulation of gamma-secretase by its lipid microenvironment. J Biol Chem. 2008;283(33):22529–22540.
   PubMed Web of Science ®Google Scholar
• Cossec JC, Simon A, Marquer C, et al. Clathrin-dependent APP endocytosis and Abeta secretion are highly sensitive to the level of plasma membrane cholesterol. Biochim Biophys Acta. 2010;1801(8):846–852.
   PubMed Web of Science ®Google Scholar
• Marquer C, Devauges V, Cossec JC, et al. Local cholesterol increase triggers amyloid precursor protein-Bace1 clustering in lipid rafts and rapid endocytosis. FASEB J. 2011;25(4):1295–1305.
   PubMed Web of Science ®Google Scholar
• Cho YY, Kwon OH, Chung S. Preferred endocytosis of amyloid precursor protein from cholesterol-enriched lipid raft microdomains. Molecules. 2020;25(23):5490.
   Web of Science ®Google Scholar
• Fabelo N, Martín V, Marín R, et al. Altered lipid composition in cortical lipid rafts occurs at early stages of sporadic Alzheimer’s disease and facilitates APP/BACE1 interactions. Neurobiol Aging. 2014;35(8):1801–1812.
   PubMed Web of Science ®Google Scholar
• Chan RB, Oliveira TG, Cortes EP, et al. Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J Biol Chem. 2012;287(4):2678–2688.
   PubMed Web of Science ®Google Scholar
• Tajima Y, Ishikawa M, Maekawa K, et al. Lipidomic analysis of brain tissues and plasma in a mouse model expressing mutated human amyloid precursor protein/tau for Alzheimer’s disease. Lipids Health Dis. 2013;12:68.
   PubMed Web of Science ®Google Scholar
• Yang D-S, Stavrides P, Saito M, et al. Defective macroautophagic turnover of brain lipids in the TgCRND8 Alzheimer mouse model: prevention by correcting lysosomal proteolytic deficits. Brain. 2014;137(12):3300–3318.
   PubMed Web of Science ®Google Scholar
• Beel AJ, Mobley CK, Kim HJ, et al. Structural studies of the transmembrane C-terminal domain of the amyloid precursor protein (APP): does APP function as a cholesterol sensor? Biochemistry. 2008;47(36):9428–9446.
   PubMed Web of Science ®Google Scholar
• Barrett PJ, Song Y, Van Horn WD, et al. The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol. Science. 2012;336(6085):1168–1171.
   PubMed Web of Science ®Google Scholar
• Song Y, Hustedt EJ, Brandon S, et al. Competition between homodimerization and cholesterol binding to the C99 domain of the amyloid precursor protein. Biochemistry. 2013;52(30):5051–5064.
   PubMed Web of Science ®Google Scholar
• Ł N, Czub J. Specific binding of cholesterol to the amyloid precursor protein: structure of the complex and driving forces characterized in molecular detail. J Phys Chem Lett. 2015;6(5):784–790.
   PubMed Web of Science ®Google Scholar
• Puglielli L, Konopka G, Pack-Chung E, et al. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat Cell Biol. 2001;3(10):905–912.
   PubMed Web of Science ®Google Scholar
• Hutter-Paier B, Huttunen HJ, Puglielli L, et al. The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer’s disease. Neuron. 2004;44(2):227–238.
   PubMed Web of Science ®Google Scholar
• Huttunen HJ, Peach C, Bhattacharyya R, et al. Inhibition of acyl-coenzyme A: cholesterol acyl transferase modulates amyloid precursor protein trafficking in the early secretory pathway. FASEB J. 2009;23(11):3819–3828.
   PubMed Web of Science ®Google Scholar
• van der Kant R, Langness VF, Herrera CM, et al. Cholesterol metabolism is a druggable axis that independently regulates tau and amyloid-β in iPSC-derived alzheimer’s disease neurons. Cell Stem Cell. 2019;24(3):363–375.e9.
   PubMed Web of Science ®Google Scholar
• Langness VF, van der Kant R, Das U, et al. Cholesterol-lowering drugs reduce APP processing to Aβ by inducing APP dimerization. Mol Biol Cell. 2021;32(3):247–259.
   PubMed Web of Science ®Google Scholar
• Feringa FM, van der Kant R. Cholesterol and Alzheimer’s disease; from risk genes to pathological effects. Front Aging Neurosci. 2021;13:690372.
   PubMed Web of Science ®Google Scholar
• Yao ZX, Papadopoulos V. Function of beta-amyloid in cholesterol transport: a lead to neurotoxicity. FASEB J. 2002;16(12):1677–1679.
   PubMed Web of Science ®Google Scholar
• Igbavboa U, Sun GY, Weisman GA. Amyloid beta-protein stimulates trafficking of cholesterol and caveolin-1 from the plasma membrane to the Golgi complex in mouse primary astrocytes. Neuroscience. 2009;162(2):328–338.
   PubMed Web of Science ®Google Scholar
• Canepa E, Borghi R, Viña J, et al. Cholesterol and amyloid-β: evidence for a cross-talk between astrocytes and neuronal cells. J Alzheimers Dis. 2011;25(4):645–653.
   PubMed Web of Science ®Google Scholar
• Shibuya Y, Niu Z, Bryleva EY, et al. Acyl-coenzyme A: cholesterol acyltransferase 1 blockage enhances autophagy in the neurons of triple transgenic Alzheimer’s disease mouse and reduces human P301L-tau content at the presymptomatic stage. Neurobiol Aging. 2015;36(7):2248–2259.
   PubMed Web of Science ®Google Scholar
• McLaurin J, Darabie AA, Morrison MR. Cholesterol, a modulator of membrane-associated Abeta-fibrillogenesis. Pharmacopsychiatry. 2003;36(Suppl 2):S130–135.
   PubMed Web of Science ®Google Scholar
• Jiang T, Yu J-T, Tian Y, et al. Epidemiology and etiology of Alzheimer’s disease: from genetic to non-genetic factors. Curr Alzheimer Res. 2013;10(8):852–867.
   PubMed Web of Science ®Google Scholar
• Zlokovic BV. Neurovascular mechanisms of Alzheimer’s neurodegeneration. Trends Neurosci. 2005;28(4):202–208.
   PubMed Web of Science ®Google Scholar
• Jeong W, Lee H, Cho S, et al. ApoE4-Induced cholesterol dysregulation and its brain cell type-specific implications in the pathogenesis of Alzheimer’s disease. Mol Cells. 2019;42(11):739–746.
   PubMed Web of Science ®Google Scholar
• Liu CC, Liu CC, Kanekiyo T, et al. Apolipoprotein E, and Alzheimer disease: risk, mechanisms, and therapy. Nat Rev Neurol. 2013;9(2):106–118.
   PubMed Web of Science ®Google Scholar
• Lin YT, Seo J, Gao F, et al. APOE4 causes widespread molecular and cellular alterations associated with alzheimer’s disease phenotypes in human iPSC-Derived brain cell types. Neuron. 2018;98(6):1141–1154.e7.
   PubMed Web of Science ®Google Scholar
• Graykowski D, Kasparian K, and Caniglia Y, et al. Neuroinflammation drives APOE genotype-dependent differential expression of neprilysin. J Neuroimmunol. 2020;346;577315.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen K, Sloan SA, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014;34(36):11929–11947.
   PubMed Web of Science ®Google Scholar
• Lyssenko NN, Praticò D. ABCA7 and the altered lipidostasis hypothesis of Alzheimer’s disease. Alzheimers Dement. 2021;17(2):164–174.
   PubMed Web of Science ®Google Scholar
• De Roeck A, Van Broeckhoven C, Sleegers K. The role of ABCA7 in Alzheimer’s disease: evidence from genomics, transcriptomics, and methylomics. Acta Neuropathol. 2019;138(2):201–220.
   PubMed Web of Science ®Google Scholar
• Nugent AA, Lin K, van Lengerich B, et al. TREM2 regulates microglial cholesterol metabolism upon chronic phagocytic challenge. Neuron. 2020;105(5):837–854.e9.
   PubMed Web of Science ®Google Scholar
• Andreone BJ, Przybyla L, Llapashtica C, et al. Alzheimer’s-associated PLCγ2 is a signaling node required for both TREM2 function and the inflammatory response in human microglia. Nat Neurosci. 2020;23(8):927–938.
   PubMed Web of Science ®Google Scholar
• Magno L, Bunney TD, Mead E, et al. TREM2/PLCγ2 signaling in immune cells: function, structural insight, and potential therapeutic modulation. Mol Neurodegener. 2021;16(1):22.
   PubMed Web of Science ®Google Scholar
• Obst J, Hall-Roberts HL, Smith TB, et al. PLCγ2 regulates TREM2 signaling and integrin-mediated adhesion and migration of human iPSC-derived macrophages. Sci Rep. 2021;11(1):19842.
   PubMed Web of Science ®Google Scholar
• Yeh FL, Wang Y, Tom I, et al. TREM2 binds to apolipoproteins, including APOE and CLU/APOJ, and thereby facilitates uptake of amyloid-beta by microglia. Neuron. 2016;91(2):328–340.
   PubMed Web of Science ®Google Scholar
• Stein EA. The power of statins: aggressive lipid-lowering. Clin Cardiol. 2003;26(4Suppl 3)):III25–31.
   PubMed Web of Science ®Google Scholar
• Lahera V, Goicoechea M, de Vinuesa SG, et al. Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins. Curr Med Chem. 2007;14(2):243–248.
   PubMed Web of Science ®Google Scholar
• Poly TN, Islam MM, Walther BA, et al. Association between use of statin and risk of dementia: a meta-analysis of observational studies. Neuroepidemiology. 2020;54(3): 214–226.
   PubMed Web of Science ®Google Scholar
• Yarchoan M, Xie SX, Kling MA, et al. Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. Brain. 2012;135(Pt 12):3749–3756.
   PubMed Web of Science ®Google Scholar
• Vaughan CJ. Prevention of stroke and dementia with statins: effects beyond lipid-lowering. Am J Cardiol. 2003;91(4A):23B–29B.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Liao JK. Pleiotropic effects of statins. - Basic research and clinical perspectives. Circ J. 2010;74(5):818–826.
   PubMed Web of Science ®Google Scholar
• Giannopoulos S, Katsanos AH, Tsivgoulis G, et al. Statins and cerebral hemodynamics. J Cereb Blood Flow Metab. 2012;32(11):1973–1976.
   PubMed Web of Science ®Google Scholar
• Simons M, Schwärzler F, Lütjohann D, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer’s disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol. 2002;52(3):346–350.
   PubMed Web of Science ®Google Scholar
• Sparks DL, Sabbagh MN, Connor DJ, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol. 2005;62(5):753–757.
   PubMedGoogle Scholar
• Miida T, Yamazaki F, Sakurai M, et al. The apolipoprotein E content of HDL in cerebrospinal fluid is higher in children than in adults. Clin Chem. 1999;45(8 Pt 1):1294–1296.
   PubMed Web of Science ®Google Scholar
• Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis. 2004;16(1):1–13.
   PubMed Web of Science ®Google Scholar
• Johnson-Anuna LN, Eckert GP, Keller JH, et al. Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex. J Pharmacol Exp Ther. 2005;312(2):786–793.
   PubMed Web of Science ®Google Scholar
• Larsson SC, Markus HS. Does treating vascular risk factors prevent dementia and Alzheimer’s disease? A systematic review and meta-analysis. J Alzheimers Dis. 2018;64(2):657–668.
   PubMed Web of Science ®Google Scholar
• Feingold KR. Cholesterol-Lowering drugs. Updated 2021 Mar 30. Feingold KR, Anawalt B, Boyce A, et al. editors. Endotext [Internet]. South Dartmouth (MA):MDText.com, Inc. 2000. Available from: https://www.ncbi.nlm.nih.gov/books/NBK395573/[Accessed October 23, 2021]
   Google Scholar
• Schultz BG, Patten DK, Berlau DJ. The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms. Transl Neurodegener. 2018;7:5.
   PubMed Web of Science ®Google Scholar
• Zhu XC, Dai WZ, Ma T. Overview the effect of statin therapy on dementia risk, cognitive changes, and its pathologic change: a systematic review and meta-analysis. Ann Transl Med. 2018;6(22):435.
   PubMed Web of Science ®Google Scholar
• Tanaka S, Fukumoto Y, Nochioka K, et al. Statins exert the pleiotropic effects through small GTP-binding protein dissociation stimulator upregulation with a resultant Rac1 degradation. Arterioscler Thromb Vasc Biol. 2013;33(7):1591–1600.
   PubMed Web of Science ®Google Scholar
• Shimizu H, Toma-Fukai S, Saijo S, et al. Structure-based analysis of the guanine nucleotide exchange factor SmgGDS reveals armadillo-repeat motifs and key regions for activity and GTPase binding. J Biol Chem. 2017;292(32):13441–13448.
   PubMed Web of Science ®Google Scholar
• Rashid M, Tawara S, Fukumoto Y, et al. Importance of Rac1 signaling pathway inhibition in the pleiotropic effects of HMG-CoA reductase inhibitors. Circ J. 2009;73(2):361–370.
   PubMed Web of Science ®Google Scholar
• Minami T, Satoh K, Nogi M, et al. Statins up-regulate SmgGDS through β1-integrin/Akt1 pathway in endothelial cells. Cardiovasc Res. 2016;109(1):151–161.
   PubMed Web of Science ®Google Scholar
• Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89–118.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Liao JK. Pleiotropic effects of statins. - Basic research and clinical perspectives. Circ J. 2010;74(5):818–826.
   PubMed Web of Science ®Google Scholar
• Li G, Shofer JB, Rhew IC, et al. Age-varying association between statin use and incident Alzheimer’s disease. J Am Geriatr Soc. 2010;58(7):1311–1317.
   PubMed Web of Science ®Google Scholar
• Cramer C, Haan MN, Galea S, et al. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology. 2008;71(5):344–350.
   PubMed Web of Science ®Google Scholar
• Dufouil C, Richard F, Fiévet N, et al. APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the three-city study. Neurology. 2005;64(9):1531–1538.
   PubMed Web of Science ®Google Scholar
• Haag MDM, Hofman A, Koudstaal PJ, et al. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The rotterdam study. J Neurol Neurosurg Psychiatry. 2009;80(1):13–17.
   PubMed Web of Science ®Google Scholar
• Horsdal HT, Olesen AV, Gasse C, et al. Use of statins and risk of hospitalization with dementia: a Danish population-based case-control study. Alzheimer Dis Assoc Disord. 2009;23(1):18–22.
   PubMed Web of Science ®Google Scholar
• Rockwood K, Kirkland S, Hogan DB, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol. 2002;59(2):223–227.
   PubMed Web of Science ®Google Scholar
• Sparks DL, Connor DJ, Sabbagh MN, et al. Circulating cholesterol levels, apolipoprotein E genotype, and dementia severity influence the benefit of atorvastatin treatment in Alzheimer’s disease: results of the Alzheimer’s disease cholesterol-lowering treatment (ADCLT) trial. Acta Neurol Scand Suppl. 2006;185:3–7.
   PubMedGoogle Scholar
• Song Y, Nie H, Xu Y, et al. Association of statin use with risk of dementia: a meta-analysis of prospective cohort studies. Geriatr Gerontol Int. 2013;13(4):817–824.
   PubMed Web of Science ®Google Scholar
• Swiger KJ, Manalac RJ, Blumenthal RS, et al. Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects. Mayo Clin Proc. 2013;88(11):1213–1221.
   PubMed Web of Science ®Google Scholar
• Richardson K, Schoen M, French B, et al. Statins and cognitive function: a systematic review. Ann Intern Med. 2013;159(10):688–697.
   PubMed Web of Science ®Google Scholar
• Sparks DL, Sabbagh M, Connor D, et al. Statin therapy in Alzheimer’s disease. Acta Neurol Scand Suppl. 2006;185:78–86.
   PubMedGoogle Scholar
• Bayorh MA, Ganafa AA, Eatman D, et al. Simvastatin and losartan enhance nitric oxide and reduce oxidative stress in salt-induced hypertension. Am J Hypertens. 2005;18(11):1496–1502.
   PubMed Web of Science ®Google Scholar
• Wanamaker BL, Swiger KJ, Blumenthal RS, et al. Cholesterol, statins, and dementia: what the cardiologist should know. Clin Cardiol. 2015;38(4):243–250.
   PubMed Web of Science ®Google Scholar
• McGuinness B, Craig D, Bullock R, et al. Statins for the prevention of dementia. Cochrane Database Syst Rev. 2016;1:CD003160.
   Google Scholar
• Huang W, Li Z, Zhao L, et al. Simvastatin ameliorate memory deficits and inflammation in clinical and mouse model of Alzheimer’s disease via modulating the expression of miR-106b. Biomed Pharmacother. 2017;92:46–57.
   PubMed Web of Science ®Google Scholar
• Zhao L, Chen T, Wang C, et al. Atorvastatin in improvement of cognitive impairments caused by amyloid β in mice: involvement of inflammatory reaction. BMC Neurol. 2016;16:18.
   PubMed Web of Science ®Google Scholar
• Shinohara M, Sato N, Kurinami H, et al. Circulating cholesterol levels, apolipoprotein E genotype, and dementia severity influence, through increase in degradation of amyloid precursor protein C-terminal fragments [APP-CTFs) and Abeta clearance. J Biol Chem. 2010;285(29):22091–22102.
   PubMed Web of Science ®Google Scholar
• Fassbender K, Simons M, Bergmann C, et al. Simvastatin strongly reduces levels of Alzheimer’s disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA. 2001;98(10):5856–5861.
   PubMed Web of Science ®Google Scholar
• Martins IJ, Berger T, Sharman MJ, et al. Cholesterol metabolism and transport in the pathogenesis of Alzheimer’s disease. J Neurochem. 2009;111(6):1275–1308.
   PubMed Web of Science ®Google Scholar
• Ostrowski SM, Wilkinson BL, Golde TE, et al. Statins reduce amyloid-beta production through inhibition of protein isoprenylation. J Biol Chem. 2007;282(37):26832–26844.
   PubMed Web of Science ®Google Scholar
• Sagare AP, Deane R, Zlokovic BV. Low-density lipoprotein receptor-related protein 1: a physiological Aβ homeostatic mechanism with multiple therapeutic opportunities. Pharmacol Ther. 2012;136(1):94–105.
   PubMed Web of Science ®Google Scholar
• Métais C, Brennan K, Mably AJ, et al. Simvastatin treatment preserves synaptic plasticity in AβPPswe/PS1dE9 mice. J Alzheimers Dis. 2014;39(2):315–329.
   PubMed Web of Science ®Google Scholar
• Matsuzawa A, Ichijo H. Redox control of cell fate by MAP kinase: physiological roles of ASK1-MAP kinase pathway in stress signaling. Biochim Biophys Acta. 2008;1780(11):1325–1336.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Zhao S, Xu N, et al. Lovastatin improves neurological outcome after nucleus basalis magnocellularis lesion in rats. Neuroscience. 2010 19;167(3):954–963.
   PubMed Web of Science ®Google Scholar
• Hamano T, Yen S-H, Gendron T, et al. Pitavastatin decreases tau levels via the inactivation of Rho/ROCK. Neurobiol Aging. 2012;33(10):2306–2320.
   PubMed Web of Science ®Google Scholar
• Wolozin B, Kellman W, Ruosseau P, et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitor. Arch Neurol. 2000;57(10):1439–1443.
   PubMed Web of Science ®Google Scholar
• Wolozin B, Wang SW, Li NC, et al. Simvastatin is associated with a reduced incidence of dementia and Parkinson’s disease. BMC Med. 2007;5(1):20.
   PubMed Web of Science ®Google Scholar
• Chou CY, Chou YC, Chou YJ, et al. Statin use, and incident dementia: a nationwide cohort study of Taiwan. Int J Cardiol. 2014;173(2):305–310.
   PubMed Web of Science ®Google Scholar
• Chao TF, Liu CJ, Chen SJ, et al. Statins and the risk of dementia in patients with atrial fibrillation: a nationwide population-based cohort study. Int J Cardiol. 2015;196:91–97.
   PubMed Web of Science ®Google Scholar
• Kim MY, Jung M, Noh Y, et al. Impact of statin use on dementia incidence in elderly men and women with ischemic heart disease. Biomedicines. 2020;8(2):30.
   Web of Science ®Google Scholar
• Green RC, McNagny SE, Jayakumar P, et al. Statin use and the risk of Alzheimer’s disease: the MIRAGE study. Alzheimers Dement. 2006;2(2):96–103.
   PubMedGoogle Scholar
• Smeeth L, Douglas I, Hall AJ, et al. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol. 2009;67(1):99–109.
   PubMed Web of Science ®Google Scholar
• Bettermann K, Arnold A, Williamson J, et al. Statins, risk of dementia, and cognitive function: secondary analysis of the ginkgo evaluation of memory study. J Stroke Cerebrovasc Dis. 2012;21:436–444.
   PubMed Web of Science ®Google Scholar
• Chen PY, Liu SK, Chen CL, et al. Long-term statin use and dementia risk in Taiwan. J Geriatr Psychiatry Neurol. 2014;27(3):165–171.
   PubMed Web of Science ®Google Scholar
• Chen JM, Chang CW, Chang TH, et al. Effects of statins on incident dementia in patients with type 2 DM: a population-based retrospective cohort study in Taiwan. PLoS One. 2014;9(2):e88434.
   PubMed Web of Science ®Google Scholar
• Rea TD, Breitner JC, Psaty BM, et al. Statin use and the risk of incident dementia: the cardiovascular health study. Arch Neurol. 2005;62(7):1047–1051.
   PubMed Web of Science ®Google Scholar
• Zandi PP, Sparks DL, Khachaturian AS, et al. Do statins reduce risk of incident dementia and Alzheimer disease? The cache county study. Arch Gen Psychiatry. 2005;62(2):217–224.
   PubMed Web of Science ®Google Scholar
• Sinyavskaya L, Gauthier S, Renoux C, et al. Comparative effect of statins on the risk of incident Alzheimer disease. Neurology. 2018;90(3):e179–e187.
   PubMed Web of Science ®Google Scholar
• Lin TK, Huang JY, Pan LF, et al. Gender- and age-related differences of statin use on incident dementia in patients with rheumatoid arthritis: a Nationwide population-based cohort study. Lipids Health Dis. 2021;20(1):37.
   PubMed Web of Science ®Google Scholar
• Samaras K, Makkar SR, Crawford JD, et al. Effects of statins on memory, cognition, and brain volume in the elderly. J Am Coll Cardiol. 2019;74(21):2554–2568.
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population-based cohort study using the QResearch database. BMJ. 2010;340:c2197.
   PubMed Web of Science ®Google Scholar
• Ancelin M-L, Carrière I, Barberger-Gateau P, et al. Lipid lowering agents, cognitive decline, and dementia: the three-city study. J Alzheimers Dis. 2012;30(3):629–637.
   PubMed Web of Science ®Google Scholar
• Mandas A, Mereu RM, Catte O, et al. Cognitive impairment and age-related vision disorders: their possible relationship and the evaluation of the use of aspirin and statins in a 65 years-and-over sardinian population. Front Aging Neurosci. 2014;6:309.
   PubMed Web of Science ®Google Scholar
• Jones RW, Kivipelto M, Feldman H, et al. The Atorvastatin/Donepezil in Alzheimer’s disease study (LEADe): design and baseline characteristics. Alzheimers Dement. 2008;4(2):145–153.
   PubMed Web of Science ®Google Scholar
• Feldman HH, Doody RS, Kivipelto M, et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: lEADe. Neurology. 2010 23;74(12):956–964.
   PubMed Web of Science ®Google Scholar
• Sano M, Bell KL, Galasko D, et al. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology. 2011;77(6):556–563.
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360(9326):7–22.
   PubMed Web of Science ®Google Scholar
• Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet. 2002;360(9346):1623–1630.
   PubMed Web of Science ®Google Scholar
• Riekse RG, Li G, Petrie EC, et al. Effect of statins on Alzheimer’s disease biomarkers in cerebrospinal fluid. J Alzheimers Dis. 2006;10(4):399–406.
   PubMed Web of Science ®Google Scholar
• Carlsson CM, Gleason CE, Hess TM, et al. Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer’s disease. J Alzheimers Dis. 2008;13(2):187–197.
   PubMed Web of Science ®Google Scholar
• Höglund K, Syversen S, Lewczuk P, et al. Statin treatment and a disease-specific pattern of beta-amyloid peptides in Alzheimer’s disease. Exp Brain Res. 2005;164(2):205–214.
   PubMed Web of Science ®Google Scholar
• Serrano-Pozo A, Vega GL, Lütjohann D, et al. Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers. Alzheimer Dis Assoc Disord. 2010;24(3):220–226.
   PubMed Web of Science ®Google Scholar
• Trial of Simvastatin in Amnestic Mild Cognitive Impairment (MCI) Patients. Full-Text view - ClinicalTrials.gov [Internet]. [cited 2020 Oct 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT00842920
   Google Scholar
• Wagstaff LR, Mitton MW, Arvik BM, et al. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy. 2003;23(7):871–880.
   PubMed Web of Science ®Google Scholar
• An K, Huang R, Tian S, et al. Statins significantly reduce mortality in patients receiving clopidogrel without affecting platelet activation and aggregation: a systematic review and meta-analysis. Lipids Health Dis. 2019;18(1):121.
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomized controlled trials Lancet. 2019;393(10170):407–415.
   Google Scholar
• Alsehli AM, Olivo G, Clemensson LE, et al. The cognitive effects of statins are modified by age. Sci Rep. 2020;10(1): 6187.
   PubMed Web of Science ®Google Scholar
• Ramkumar S, Raghunath A, Raghunath S. Statin therapy: review of safety and potential side effects. Acta Cardiol Sin. 2016;32(6):631–639.
   PubMed Web of Science ®Google Scholar
• Strom BL, Schinnar R, Karlawish J, et al. Statin therapy and risk of acute memory impairment. JAMA Intern Med. 2015;175(8):1399–1405.
   PubMed Web of Science ®Google Scholar
• Turner RM, Pirmohamed M. Statin-related myotoxicity: a comprehensive review of pharmacokinetic, pharmacogenomic and muscle components. J Clin Med. 2019 20;9(1):22.
   PubMed Web of Science ®Google Scholar
• Sirtori CR. The pharmacology of statins. Pharmacol Res. 2014;88:3–11.
   PubMed Web of Science ®Google Scholar
• Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532–2561.
   PubMed Web of Science ®Google Scholar
• Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008;8(6):373–418.
   PubMed Web of Science ®Google Scholar
• Cunningham EL, McGuinness B, Herron B, et al. Dementia. Ulster Med J. 2015;84(2):79–87.
   PubMedGoogle Scholar
• Torrandell-Haro G, Branigan GL, Vitali F, et al. Statin therapy and risk of Alzheimer’s and age-related neurodegenerative diseases. Alzheimers Dement. 2020;6(1):e12108.
   Web of Science ®Google Scholar
• Geifman N, Brinton RD, Kennedy RE, et al. Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer’s disease. Alzheimers Res Ther. 2017;9(1):10.
   PubMed Web of Science ®Google Scholar